PARIS--(BUSINESS WIRE)--BioAlliance Pharma SA (Paris:BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that the Company has received marketing authorization for Loramyc® (miconazole Lauriad) from France’s regulatory body, AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé).
